
The Untold Story of Novo Nordisk: A Glimpse into Its Potential Pharmaceutical Revolution
Novo Nordisk is poised for a 45.6% stock recovery, driven by aggressive innovation and strategic foresight. The company plans to enter the GLP-1 weight loss market with a groundbreaking oral pill, competing directly with Eli Lilly. Regulatory approval in the U.S. could